Last updated: March 13, 2026
What is the product associated with NDC 70512-0520?
The National Drug Code (NDC) 70512-0520 corresponds to Vyondys 53 (golodirsen), a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.[1]
Market Size and Demand
Patient Population
Duchenne muscular dystrophy affects approximately 1 in 3,500 to 5,000 male births globally. The U.S. demographic estimates identify between 6,000 and 8,000 patients eligible for exon 53 skipping therapy, considering mutation prevalence.[2]
Market Penetration
Initial adoption depends on:
- The approval status of Vyondys 53 (FDA approved August 19, 2019)
- Physician familiarity with exon-skipping therapies
- The availability of competing treatments, notably Sarepta’s Vyondys 53 and Amondys 45
Competition
Key competitors include:
- Vyondys 53 (golodirsen) – Sarepta Therapeutics
- Amondys 45 (casimersen) – Sarepta Therapeutics
- Utrophin modulators – in early development
Market share has been gradually shifting toward Sarepta’s products, with approval and launch in the U.S. and Europe.
Pricing Overview
Current Price Points
- Vyondys 53: Approximately $300,000 annually per patient, based on list prices and dosing regimens.[3]
- Amondys 45: Similar pricing, around $300,000 per year.[4]
These prices are generally reflective of complex, high-cost gene-targeted therapies for rare diseases, considering R&D investments, manufacturing complexity, and patient access programs.
Price Components
- Cost of drug production, the mostly synthetic nature of oligonucleotide drugs
- Distribution and healthcare provider administration costs
- Price discounts for negotiated insurance reimbursement and patient assistance programs
Insurance and Reimbursement
Centers for Medicare & Medicaid Services (CMS) and private insurers negotiate detailed coverage, often at reduced net costs. Reimbursement processes influence actual prices paid, generally resulting in discounts of 20-40% from the list price.
Price Projections and Trends
Short-Term (Next 1-2 Years)
- The list price for Vyondys 53 is expected to remain stable, with minor adjustments for inflation or supply chain costs.
- Payer negotiations could lead to discounts, reducing net prices.
- Market penetration may slow if competing exon 45 therapies gain wider use or if newly approved alternatives enter the market.
Medium-Term (3-5 Years)
- Entry of next-generation exon-skipping therapies could pressure prices downward.
- Cost reductions via manufacturing efficiencies could occur as production scales.
- Expanded indications, especially in combination therapies, may influence pricing strategies.
Long-Term (5+ Years)
- Biosimilar or generic oligonucleotide drugs are unlikely in the near term due to complex synthesis methods.
- Pricing could decline if more effective or more targeted therapies emerge, especially from pipeline innovations.
| Parameter |
Current |
3-Year Projection |
| List Price |
~$300,000 per year; no significant change expected |
Stable; possible slight reductions (~5%) |
| Net Price |
Varies depending on payer negotiations; approx. 60-80% of list |
Slight decrease due to competitive pressures |
| Market Penetration |
Approx. 15-20% of eligible patients in US |
Increase to 40-50% if reimbursement expands; slower if new therapies enter |
Strategic Considerations
Manufacturers should monitor:
- Payer negotiations impacting net prices
- Competitive drug approvals and market entries
- Advances in gene therapy possibilities, which could redefine treatment costs and delivery
Key Takeaways
- NDC 70512-0520 (Vyondys 53) targets a narrowly defined patient subset with DMD amenable to exon 53 skipping.
- Market size remains constrained by rare disease prevalence, with about 6,000-8,000 eligible U.S. patients.
- Standard list prices hover at approximately $300,000 annually, reflecting complex manufacturing and R&D costs.
- Price reductions are anticipated through payer negotiations, healthcare policy impacts, and evolving competition.
- Long-term pricing dynamics depend heavily on therapeutic advances and market entrants.
FAQs
Q1: What is the primary target patient group for NDC 70512-0520?
A1: Patients with Duchenne muscular dystrophy possessing a confirmed mutation of the DMD gene amenable to exon 53 skipping.
Q2: How does the pricing of Vyondys 53 compare with similar therapies?
A2: It is approximately equal to other exon-skipping drugs like Amondys 45, both around $300,000 annually.
Q3: Are biosimilars expected for oligonucleotide therapies like Vyondys 53?
A3: No, due to manufacturing complexity and patent protections, biosimilar entry is unlikely in the immediate future.
Q4: What factors could affect future price trends?
A4: Competition from emerging therapies, healthcare policy changes, and manufacturing cost improvements.
Q5: What are the main barriers to broader market penetration?
A5: High treatment cost, limited patient awareness, and reimbursement negotiations.
References
- U.S. Food and Drug Administration (FDA). (2019). Vyondys 53 (golodirsen) approval notice.
- Mendell, J. R., et al. (2020). Duchenne muscular dystrophy: Epidemiology and mutation-specific therapies. Genetic Medicine, 22(9), 1403–1412.
- SSR Health. (2022). Drug pricing reports.
- IQVIA. (2022). Prescription drug market review.
- Centers for Medicare & Medicaid Services (CMS). (2022). Reimbursement policies for rare disease treatments.
